Compile Data Set for Download or QSAR
Report error Found 34 of affinity data for UniProtKB/TrEMBL: P09086
TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50: 42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330054(US9663528, 64 | US9732092, Compound 64 | (2R,5S,13...)
Affinity DataIC50: 94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330049(US9663528, 45 | (13aS)-8-hydroxy-7,9-dioxo-N-(2,4,...)
Affinity DataIC50: 137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM448201(US10689399, Compound 40)
Affinity DataIC50: 204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350693(US9795602, Compound 29)
Affinity DataIC50: 216nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330039(US9663528, 2 | US9732092, Compound 2 | (2R,5S,13aR...)
Affinity DataIC50: 240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330040(US9663528, 3 | (2S,5R,13aS)-N-(2,4-difluorobenzyl)...)
Affinity DataIC50: 250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM448200(US10689399, Compound 39)
Affinity DataIC50: 358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM448216(US10689399, Compound 100)
Affinity DataIC50: 450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330052(US9663528, 55 | US9732092, Compound 55 | (1R,4S,12...)
Affinity DataIC50: 476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330048(US9663528, 42 | (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N...)
Affinity DataIC50: 487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM448198(US10689399, Compound 13)
Affinity DataIC50: 610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM448213(US10689399, Compound 96)
Affinity DataIC50: 1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330060(US9663528, 99 | US9732092, Compound 99 | (1R,3S,4R...)
Affinity DataIC50: 1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330041(US9663528, 5 | (4R,12aS)-N-(1-(2,4-difluorophenyl...)
Affinity DataIC50: 2.23E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350694(US9795602, Compound 58)
Affinity DataIC50: 2.49E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350830(US9795602, Compound 59)
Affinity DataIC50: 2.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330047(US9663528, 41 | US9732092, Compound 41 | (1R,4S,12...)
Affinity DataIC50: 2.82E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330059(US9663528, 98 | US9732092, Compound 98 | (1S,4R,12...)
Affinity DataIC50: 3.73E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330055(US9663528, 77 | US9732092, Compound 77 | (1R,4S,12...)
Affinity DataIC50: 3.83E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330051(US9663528, 48 | (1S,4R,12aS)-N-(2,4-difluorobenzyl...)
Affinity DataIC50: 4.91E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330050(US9663528, 47 | US9732092, Compound 47 | (1R,4S,12...)
Affinity DataIC50: 6.20E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350834(US9795602, Compound 12)
Affinity DataIC50: 6.40E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330042(US9663528, 11 | US9732092, Compound 11 | (2S,5R,13...)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350831(US9795602, Compound 31)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350832(US9795602, Compound 32)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330057(US9663528, 83 | US9732092, Compound 83 | (1S,4R,12...)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330056(US9663528, 82 | (1S,3R,4R,12aR)-3-fluoro-7-hydroxy...)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350833(US9795602, Compound 39)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350835(US9795602, Compound 25b)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350836(US9795602, Compound 28)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330044(US9663528, 36 | US9732092, Compound 36 | (2S,5R)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50576849(CHEMBL4876008)
Affinity DataIC50: 5.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50228403(8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-m...)
Affinity DataIC50: 8.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2016
Entry Details Article
PubMed